Nandrobolin Nandrolone Decanoate 250mg/ml 10 Ampoules
Nandrobolin-250 (ampoules) is widely known as Deca-Durabolin, Nandrolone Decanoate
Other alternative names for Nandrobolin-250 (ampoules) (Nandrolone Decanoate): Alpha-Pharma Nandrolone Decanoate, Nandrolone Decanoate, Duraboline, Deca-Durabolin 250mg 10, Nandrobolin-250 (ampoules) 250mg 10.
All of these are different brands of the same active substance – Nandrolone Decanoate
Nandrobolin (ampoules) – Deca-Durabolin Nandrolone Decanoate 250mg
Nandrolone decanoate (USAN, BAN) (brand names Deca-Durabolin, Deca-Durabol, Decaneurabol, Metadec, Retabolil), or nandrolone decylate, also known as 19-nortestosterone 17β-decanoate or 17β-[(1-oxodecyl)oxy]estr-4-en-3-one, is a synthetic androgen and anabolic steroid and a nandrolone ester. It was introduced in 1962. Along with nandrolone phenylpropionate (NPP), nandrolone decanoate is one of the most widely used nandrolone esters, and is marketed in many countries throughout the world, including in the United States, Canada, and United Kingdom. Both nandrolone decanoate and NPP are prodrugs of nandrolone.
Nandrolone (INN, BAN), also known as 19-nortestosterone or 19-norandrostenolone, is a synthetic anabolic-androgenic steroid (AAS) derived from testosterone. The drug itself is inactive orally due to its lack of a 17α-alkyl group (which renders it vulnerable to extensive first-pass metabolism) and is not actually employed in medicine. Instead, nandrolone is used in the form of a variety of long-acting prodrug esters (see nandrolone ester) for intramuscular injection, the most common of which are nandrolone decanoate (Deca-Durabolin, Eubolin, Retabolil) and, to a lesser extent, nandrolone phenylpropionate (Durabolin, Fenobolin).
The positive effects of the drug include muscle growth, appetite stimulation and increased red blood cell production, and bone density. Clinical studies have shown it to be effective in treating anemia, osteoporosis and some forms of neoplasia including breast cancer, and also acts as a progestin-based contraceptive.
Unlike testosterone and certain other anabolic steroids, nandrolone is not potentiated in androgenic tissues like the scalp, skin, and prostate, and hence, deleterious effects in these tissues are lessened to a degree. This is because nandrolone is metabolized by 5α-reductase to the much weaker androgen 5α-dihydronandrolone (DHN), which has both reduced affinity for the androgen receptor (AR) relative to nandrolone in vitro and weaker androgenic activity in vivo. The lack of alkylation on the 17α-carbon drastically reduces the hepatotoxic potential of nandrolone. Estrogenic effects resulting from reaction with aromatase are also reduced due to lessened enzyme interaction, but effects such as gynaecomastia and reduced libido may still occur at sufficiently high doses.
Nandrolone has a very high ratio of anabolic to androgenic action. In fact, nandrolone-like AAS like nandrolone itself and trenbolone are said to have among the highest ratio of anabolic to androgenic effect of all AAS. This is attributed to the fact that, whereas testosterone is potentiated via conversion into dihydrotestosterone (DHT) in androgenic tissues, the opposite is true with nandrolone and similar AAS (i.e., other 19-nortestosterone derivatives). As such, nandrolone-like AAS, namely nandrolone esters, are the most frequently used AAS in clinical settings in which anabolic effects are desired; for instance, in the treatment of AIDS-associated cachexia, severe burns, and chronic obstructive pulmonary disease. However, AAS with a very high ratio of anabolic to androgenic action like nandrolone still have significant androgenic effects and can produce symptoms of virilization like hirsutism and voice deepening in women and children with extended use.
Nandrolone use is directly detectable in hair or indirectly detectable in urine by testing for the presence of 19-norandrosterone, a metabolite. The International Olympic Committee has set a limit of 2.0 μg/L of 19-norandrosterone in urine as the upper limit, beyond which an athlete is suspected of doping. In the largest nandrolone study performed on 621 athletes at the 1998 Nagano Olympic Games, no athlete tested over 0.4 μg/L. 19-Norandrosterone was identified as a trace contaminant in commercial preparations of androstenedione, which until 2004 was available without a prescription as a dietary supplement in the U.S.
A number of nandrolone cases in athletics occurred in 1999, which included high-profile athletes such as Merlene Ottey, Dieter Baumann and Linford Christie. However, the following year the detection method for nandrolone at the time was proved to be faulty. Mark Richardson, a British Olympic relay runner who tested positive for the substance, gave a significant amount of urine samples in a controlled environment and delivered a positive test for the drug, demonstrating that false positives could occur, which led to an overhaul of his competitive ban.
Nandrolone use as a doping agent in sports
Nandrolone was first synthesized in 1950. It was first introduced, as nandrolone phenylpropionate and then as nandrolone decanoate, in 1959 and 1962, respectively.
Nandrolone was probably among the first steroids to be used as a doping agent in sports in the 1960s. It has been banned at the Olympics since 1974.
Known under the names
Deca, Deca Durabolin, Nandrolone Decanoate
Nandrobolin is indicated for treatment of chronic infections, recovery after extensive surgery or severe trauma which requires reversal of catabolic effect, as well as treatment of anemia, carcinoma and turner’s syndrome.
Each carton contains 10 ampoules of 1ml (250mg/ml).